Oragenics Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Oragenics.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.4%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Oragenics no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NYSEAM:OGEN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2024	N/A	-20	-8	-8	N/A
6/30/2024	0	-20	-7	-7	N/A
3/31/2024	0	-20	-8	-8	N/A
12/31/2023	0	-21	-7	-7	N/A
9/30/2023	0	-10	-9	-9	N/A
6/30/2023	0	-12	-11	-11	N/A
3/31/2023	0	-13	-12	-12	N/A
12/31/2022	0	-14	-15	-15	N/A
9/30/2022	0	-14	-15	-15	N/A
6/30/2022	0	-15	-16	-16	N/A
3/31/2022	0	-15	-15	-15	N/A
12/31/2021	0	-16	-14	-13	N/A
9/30/2021	N/A	-18	-15	-15	N/A
6/30/2021	N/A	-18	-15	-15	N/A
3/31/2021	N/A	-26	-17	-17	N/A
12/31/2020	N/A	-26	-17	-17	N/A
9/30/2020	N/A	-26	-17	-17	N/A
6/30/2020	N/A	-25	-16	-16	N/A
3/31/2020	N/A	-17	-15	-15	N/A
12/31/2019	N/A	-16	-13	-13	N/A
9/30/2019	N/A	-15	-12	-12	N/A
6/30/2019	N/A	-15	-11	-11	N/A
3/31/2019	N/A	-13	-10	-10	N/A
12/31/2018	N/A	-11	-9	-9	N/A
9/30/2018	N/A	-10	-8	-7	N/A
6/30/2018	N/A	-8	N/A	-6	N/A
3/31/2018	N/A	-7	N/A	-6	N/A
12/31/2017	N/A	-7	N/A	-6	N/A
9/30/2017	N/A	-8	N/A	-7	N/A
6/30/2017	N/A	-8	N/A	-7	N/A
3/31/2017	N/A	-8	N/A	-7	N/A
12/31/2016	N/A	-8	N/A	-7	N/A
9/30/2016	N/A	-8	N/A	-7	N/A
6/30/2016	N/A	-8	N/A	-6	N/A
3/31/2016	0	-13	N/A	-5	N/A
12/31/2015	N/A	-12	N/A	-5	N/A
9/30/2015	0	-11	N/A	-5	N/A
6/30/2015	0	-10	N/A	-5	N/A
3/31/2015	1	-5	N/A	-5	N/A
12/31/2014	1	-6	N/A	-6	N/A
9/30/2014	1	-8	N/A	-6	N/A
6/30/2014	1	-16	N/A	-6	N/A
3/31/2014	1	-16	N/A	-7	N/A
12/31/2013	1	-16	N/A	-7	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de OGEN es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de OGEN crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de OGEN crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de OGEN crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de OGEN crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de OGEN se prevé que sea elevada dentro de 3 años.

Oragenics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased to US$2.25

Price target increased to US$2.25

Price target decreased to US$2.25

Price target decreased to US$2.25

Price target increased to US$2.25

Recent updates

Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Oragenics, Inc. Plans to Initiate Phase II Clinical Trials

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $4.453593 million.

Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $4.453593 million.

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

New major risk - Financial position

First half 2024 earnings released: US$1.21 loss per share (vs US$2.92 loss in 1H 2023)

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients

Oragenics, Inc. has completed a Follow-on Equity Offering.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics Announces NYSE American Acceptance of Plan of Compliance

Oragenics, Inc. Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial

First quarter 2024 earnings released: US$0.70 loss per share (vs US$1.41 loss in 1Q 2023)

Full year 2023 earnings released: US$9.18 loss per share (vs US$7.11 loss in FY 2022)

Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $2.1 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion

New major risk - Share price stability

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. (NYSEAM:OGEN) completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Third quarter 2023 earnings released: US$0.85 loss per share (vs US$1.99 loss in 3Q 2022)

Oragenics, Inc., Annual General Meeting, Dec 14, 2023

Oragenics Announces Directorate Appointments

Oragenics, Inc. (NYSEAM:OGEN) entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Second quarter 2023 earnings released: US$1.51 loss per share (vs US$1.85 loss in 2Q 2022)

Oragenics, Inc. announced that it has received $0.85 million in funding

Oragenics, Inc. Announces the Award of Grant from CQDM for the Collaborative Development of a Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate

Insufficient new directors

Oragenics, Inc. Regains Compliance with NYSE American

Oragenics, Inc. Reports Favorable Toxicology Results for Its Covid-19 Intranasal Vaccine Candidate

Oragenics, Inc. Receives NYSE American Notice Regarding Compliance with Section 1003(f)(v)

Oragenics, Inc. Announces Board Changes

Oragenics, Inc. Appoints Kimberly Murphy as Secretary and Treasurer

Oragenics, Inc. Announces Resignation of Michael Sullivan as Chief Financial Officer, Effective from December 14, 2022

Price target increased to US$2.25

Oragenics, Inc., Annual General Meeting, Dec 16, 2022

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

Price target increased to US$2.25

Oragenics, Inc. Appoints Kimberly M. Murphy as Chief Executive Officer

Oragenics Announces Publication of Positive Data for Its NT-Cov2-1 Intranasal Covid-19 Vaccine Candidate in Scientific Reports

Price target decreased to US$2.25

Executive Chairman recently bought US$66k worth of stock

Price target decreased to US$2.25

Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript

Oragenics, Inc. Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations SARS-CoV-2 Vaccine Candidate

Price target increased to US$2.25

Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento